{"entity":{"id":"nct03964727","kind":"trial","name":"Study of Sacituzumab Govitecan in Participants With Metastatic Solid Tumors","aka":["TROPiCS-03"],"tldr":"A phase 2 trial of Sacituzumab govitecan in advanced solid tumours, run by Gilead Sciences, active and no longer recruiting.","summary":"Study of Sacituzumab Govitecan in Participants With Metastatic Solid Tumors is a phase 2 interventional study registered as NCT03964727 by Gilead Sciences, with 227 participants enrolled, started 2019-10-15 and due to reach its primary completion in 2025-01-15. Interventions recorded: Sacituzumab Govitecan-hziy. Results have been posted on the registry.","status":"active","asOf":"2026-09-22","links":[{"label":"ClinicalTrials.gov NCT03964727","url":"https://clinicaltrials.gov/study/NCT03964727"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":["adc","topoisomerase-inhibitors"],"targets":[],"drugs":["sacituzumab-govitecan"],"companies":["gilead"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT03964727","phase":"2","setting":"A Phase 2 Open-Label Study of Sacituzumab Govitecan (IMMU-132) in Subjects With Metastatic Solid Tumors","sponsor":"Gilead Sciences","started":"2019-10-15","startedType":"actual","yearReported":2026,"enrolled":227,"enrolledBasis":"registry","outcomes":[{"endpoint":"Objective Response Rate (ORR) According to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 by Investigator's Assessment","primary":true,"unit":"%","arms":[{"name":"Cohort 1 Group 1: NSCLC [Adenocarcinoma + SCC]","n":31,"value":12.9,"note":"95% CI 3.6 to 29.8; Figures from the ClinicalTrials.gov results section (first posted 2026-01-30), not from a publication"},{"name":"Cohort 1 Group 2: NSCLC (Adenocarcinoma)","n":34,"value":5.9,"note":"95% CI 0.7 to 19.7"},{"name":"Cohort 1 Group 3: NSCLC (SCC)","n":31,"value":6.5,"note":"95% CI 0.8 to 21.4"},{"name":"Cohort 2: HNSCC","n":43,"value":16.3,"note":"95% CI 6.8 to 30.7"},{"name":"Cohort 3: EC","n":41,"value":26.8,"note":"95% CI 14.2 to 42.9"},{"name":"Cohort 4: ES-SCLC","n":43,"value":44.2,"note":"95% CI 29.1 to 60.1"}],"source":"https://clinicaltrials.gov/study/NCT03964727?tab=results"},{"endpoint":"Overall Survival (OS)","unit":"months","arms":[{"name":"Cohort 1 Group 1: NSCLC [Adenocarcinoma + SCC]","n":31,"value":14.26,"note":"95% CI 4.34 to 23.72; Figures from the ClinicalTrials.gov results section (first posted 2026-01-30), not from a publication"},{"name":"Cohort 1 Group 2: NSCLC (Adenocarcinoma)","n":34,"value":11.02,"note":"95% CI 4.24 to 20.47"},{"name":"Cohort 1 Group 3: NSCLC (SCC)","n":31,"value":7.29,"note":"95% CI 5.16 to 10.22"},{"name":"Cohort 2: HNSCC","n":43,"value":8.97,"note":"95% CI 7.52 to 12.22"},{"name":"Cohort 3: EC","n":41,"value":14.95,"note":"95% CI 5.88 to 21.42"},{"name":"Cohort 4: ES-SCLC","n":43,"value":11.73,"note":"95% CI 6.57 to 14.72"}],"source":"https://clinicaltrials.gov/study/NCT03964727?tab=results"}]},"route":"/trials/nct03964727/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"technology":[{"id":"adc","kind":"technology","name":"Antibody-drug conjugate (ADC)","route":"/technologies/adc/"},{"id":"topoisomerase-inhibitors","kind":"technology","name":"Topoisomerase-I inhibitors (and ADC payloads)","route":"/technologies/topoisomerase-inhibitors/"}],"drug":[{"id":"sacituzumab-govitecan","kind":"drug","name":"Sacituzumab govitecan","route":"/drugs/sacituzumab-govitecan/"}],"company":[{"id":"gilead","kind":"company","name":"Gilead Sciences (incl. Kite)","route":"/companies/gilead/"}]}}